#JS212
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH P...

Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org

#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
April 20, 2026 at 10:31 PM
📰 #Finance

"SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced…"
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
financialpost.com
April 20, 2026 at 10:30 PM